PMID- 37187759
OWN - NLM
STAT- MEDLINE
DCOM- 20230517
LR  - 20230518
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Development of a high-resolution mass-spectrometry-based method and software for 
      human leukocyte antigen typing.
PG  - 1188381
LID - 10.3389/fimmu.2023.1188381 [doi]
LID - 1188381
AB  - INTRODUCTION: The human leukocyte antigen (HLA) system plays a critical role in 
      the human immune system and is strongly associated with immune recognition and 
      rejection in organ transplantation. HLA typing method has been extensively 
      studied to increase the success rates of clinical organ transplantation. However, 
      while polymerase chain reaction sequence-based typing (PCR-SBT) remains the gold 
      standard, cis/trans ambiguity and nucleotide sequencing signal overlay during 
      heterozygous typing present a problem. The high cost and low processing speed of 
      Next Generation Sequencing (NGS) also render this approach inadequate for HLA 
      typing. METHODS AND MATERIALS: To address these limitations of the current HLA 
      typing methods, we developed a novel typing technology based on nucleic acid mass 
      spectrometry (MS) of HLA. Our method takes advantage of the high-resolution mass 
      analysis function of MS and HLAMSTTs (HLA MS Typing Tags, some short fragment PCR 
      amplification target products) with precise primer combinations. RESULTS: We 
      correctly typed HLA by measuring the molecular weights of HLAMSTTs with single 
      nucleotide polymorphisms (SNPs). In addition, we developed a supporting HLA MS 
      typing software to design PCR primers, construct the MS database, and select the 
      best-matching HLA typing results. With this new method, we typed 16 HLA-DQA1 
      samples, including 6 homozygotes and 10 heterozygotes. The MS typing results were 
      validated by PCR-SBT. DISCUSSION: The MS HLA typing method is rapid, efficient, 
      accurate, and readily applicable to typing of homozygous and heterozygous 
      samples.
CI  - Copyright (c) 2023 Wang, Sun, Zhu, Xu and Zhou.
FAU - Wang, Kun
AU  - Wang K
AD  - Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
FAU - Sun, Zetao
AU  - Sun Z
AD  - Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, Guangdong, 
      China.
FAU - Zhu, Fei
AU  - Zhu F
AD  - Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
FAU - Xu, Yunping
AU  - Xu Y
AD  - Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, Guangdong, 
      China.
FAU - Zhou, Feng
AU  - Zhou F
AD  - Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and 
      Cancer Invasion, Minister of Education, and Institutes of Biomedical Sciences, 
      Fudan University, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230428
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Humans
MH  - Histocompatibility Testing/methods
MH  - Sequence Analysis, DNA
MH  - *High-Throughput Nucleotide Sequencing/methods
MH  - Polymerase Chain Reaction
MH  - *Software
PMC - PMC10175642
OTO - NOTNLM
OT  - HLA typing
OT  - cis/trans ambiguity
OT  - mass spectrometry
OT  - nucleic acid mass spectrometry
OT  - polymorphism
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/16 01:09
MHDA- 2023/05/17 06:42
PMCR- 2023/01/01
CRDT- 2023/05/15 19:30
PHST- 2023/03/22 00:00 [received]
PHST- 2023/04/12 00:00 [accepted]
PHST- 2023/05/17 06:42 [medline]
PHST- 2023/05/16 01:09 [pubmed]
PHST- 2023/05/15 19:30 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1188381 [doi]
PST - epublish
SO  - Front Immunol. 2023 Apr 28;14:1188381. doi: 10.3389/fimmu.2023.1188381. 
      eCollection 2023.